Clinical Research Directory

Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.

Sponsor: Cairo University

Summary

The goal of this clinical trial is to learn if topical application of crisaborole 2% ointment can treat stable patches of facial vitiligo in pediatrics and adult patients of both genders. It will also learn about the safety of crisaborole 2% ointment. The main questions it aims to answer is: * Does crisaborole 2% ointment work effectively in stable localized facial vitiligo in pediatrics and adults? * is crisaborole 2% ointment well tolerated in stable localized facial vitiligo in pediatrics and adults? * Is crisaborole 2% ointment comparable to tacrolimus 0.1% ointment in terms of efficacy and safety in stable localized facial vitiligo in pediatrics and adults? Researchers will compare crisaborole 2% ointment to tacrolimus 0.1% ointment to see if crisaborole works as effective and is as well-tolerated. Participants will: * apply topical crisaborole 2% ointment or tacrolimus 0.1% ointment twice daily for 6 months (or until complete repigmentation, whichever earlier) to patches of stable facial vitiligo. * Visit the clinic twice every week for Excimer light sessions, checkups, and photography. * Keep a diary of their symptoms.

Key Details

Conditions

Interventions

Locations (1)